<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sumpio BJ</submitter><funding>NIDDK NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>435-445</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11535488</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(9)</volume><pubmed_abstract>&lt;b>Introduction:&lt;/b> Diabetes mellitus (DM) affects over 422 million people globally. Patients with DM are subject to a myriad of complications, of which diabetic foot ulcers (DFUs) are the most common with ∼25% chance of developing these wounds throughout their lifetime. &lt;b>Innovation:&lt;/b> Currently there are no therapeutic RNAs approved for use in DFUs. Use of dressings containing novel layer-by-layer (LbL)-formulated therapeutic RNAs that inhibit PHD2 and miR-210 can significantly improve diabetic wound healing. These dressings provide sustained release of therapeutic RNAs to the wounds locally without systemic side effects. &lt;b>Clinical Problem Addressed:&lt;/b> Diabetic foot wounds are difficult to heal and often result in significant patient morbidity and mortality. &lt;b>Materials and Meth</pubmed_abstract><journal>Advances in wound care</journal><pubmed_title>Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds.</pubmed_title><pmcid>PMC11535488</pmcid><funding_grant_id>F30 DK130564</funding_grant_id><funding_grant_id>T32 GM144273</funding_grant_id><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Johnston BH</pubmed_authors><pubmed_authors>Sumpio BJ</pubmed_authors><pubmed_authors>Dallas A</pubmed_authors><pubmed_authors>Wang E</pubmed_authors><pubmed_authors>Mezghani I</pubmed_authors><pubmed_authors>Berger AG</pubmed_authors><pubmed_authors>Ilves H</pubmed_authors><pubmed_authors>Veves A</pubmed_authors><pubmed_authors>Contreras M</pubmed_authors><pubmed_authors>Hammond PT</pubmed_authors><pubmed_authors>Theocharidis G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds.</name><description>&lt;b>Introduction:&lt;/b> Diabetes mellitus (DM) affects over 422 million people globally. Patients with DM are subject to a myriad of complications, of which diabetic foot ulcers (DFUs) are the most common with ∼25% chance of developing these wounds throughout their lifetime. &lt;b>Innovation:&lt;/b> Currently there are no therapeutic RNAs approved for use in DFUs. Use of dressings containing novel layer-by-layer (LbL)-formulated therapeutic RNAs that inhibit PHD2 and miR-210 can significantly improve diabetic wound healing. These dressings provide sustained release of therapeutic RNAs to the wounds locally without systemic side effects. &lt;b>Clinical Problem Addressed:&lt;/b> Diabetic foot wounds are difficult to heal and often result in significant patient morbidity and mortality. &lt;b>Materials and Meth</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-05-29T18:45:57.027Z</modification><creation>2026-04-08T05:43:12.536Z</creation></dates><accession>S-EPMC11535488</accession><cross_references><pubmed>38183631</pubmed><doi>10.1089/wound.2023.0056</doi></cross_references></HashMap>